GCK Glu279Ter (MODY2)

GCK Glu279Ter — The Mutation That Founded MODY2

In 1992, a French research team identified the first nonsense mutation in the
glucokinase gene and, in doing so, answered a decades-old question: why do some
families pass down mild diabetes through every generation as if it were hair
colour? The answer was an amber stop codon — a single nucleotide change (c.835G>T)
that turns codon 279 from GAG (glutamic acid) to TAG (stop), truncating the
glucokinase protein at position 279 and abolishing its function in the affected
allele. Vionnet et al. 1992 | Vionnet N et al. Nonsense mutation in the
glucokinase gene causes early-onset non-insulin-dependent diabetes mellitus.
Nature, 1992 — published in Nature —
was the first direct proof that a mutation in a glucose-metabolism enzyme causes
human diabetes. This variant is OMIM 138079.0001: allelic variant number one in
the glucokinase gene.

The Mechanism

Glucokinase | Glucokinase (hexokinase-4) phosphorylates glucose to glucose-6-phosphate
in pancreatic beta cells and hepatocytes. Its sigmoidal kinetics and low glucose
affinity make it uniquely suited as a "glucose sensor" — activity rises steeply
above approximately 5 mmol/L, triggering insulin release proportionally to
glucose concentration is the molecular
switch that decides when the beta cell releases insulin. The switch only flips
when glucose is high enough — specifically above the enzyme's half-saturation
concentration of roughly 7–8 mmol/L under physiological conditions. Glu279 is
located in a structurally important region of the glucokinase catalytic domain;
the p.Glu279Ter nonsense variant introduces a premature stop codon | A stop codon
terminates protein synthesis, producing a truncated, non-functional protein. The
resulting mRNA is often degraded by nonsense-mediated mRNA decay, so no
truncated protein accumulates — the allele is functionally null that truncates the protein by 186
amino acids, rendering it completely non-functional.

In a heterozygous carrier, one fully functional GCK copy remains. Half-normal
glucokinase activity shifts the glucose set-point for insulin secretion upward
by approximately 1.4–2.0 mmol/L. The pancreas defends a higher fasting glucose —
roughly 5.5–8.0 mmol/L (99–144 mg/dL) — throughout life. This is not beta-cell
failure; it is a fixed recalibration of the glucose thermostat, present from
conception, stable over decades, and not progressive.

The Evidence

Vionnet et al. 1992 | Vionnet N et al. Nonsense mutation in the glucokinase gene
causes early-onset non-insulin-dependent diabetes mellitus. Nature, 1992 identified the Glu279Ter variant in a
French family through single-strand conformation polymorphism analysis of GCK
exon 7. All affected family members with this stop codon had the characteristic
MODY phenotype — early-onset mild hyperglycemia with autosomal dominant
transmission. This was published simultaneously with Froguel et al. | Froguel P
et al. Close linkage of glucokinase locus on chromosome 7p to early-onset
non-insulin-dependent diabetes mellitus. Nature, 1992, which established glucokinase linkage
in 16 French MODY families, and Hattersley et al. | Hattersley AT et al.
Linkage of type 2 diabetes to the glucokinase gene. Lancet, 1992 confirming the same in a British
five-generation pedigree.

The definitive natural history comes from Velho et al. 1997 | Velho G et al.
Identification of 14 new glucokinase mutations and description of the clinical
profile of 42 MODY-2 families. Diabetologia, 1997:
260 subjects across 42 families showed mild fasting hyperglycemia, fewer than 50%
with overt diabetes by WHO criteria, and a strikingly low prevalence of
microvascular complications despite lifelong glucose elevation. Chakera et al.
2015 | Chakera AJ et al. Recognition and Management of Individuals With
Hyperglycemia Because of a Heterozygous Glucokinase Mutation. Diabetes Care,
2015 synthesized this evidence into
the current management consensus: fasting glucose 5.4–8.3 mmol/L and HbA1c
5.8–7.6% are expected and stable; even after 50 years of this elevation, patients
do not develop significant diabetic retinopathy or nephropathy; glucose-lowering
treatment is ineffective and not recommended outside pregnancy.

Practical Actions

The most important clinical consequence of identifying this variant is
preventing misdiagnosis and unnecessary treatment. An estimated 80% of
GCK-MODY individuals in the general population carry a diagnosis of type 1 or
type 2 diabetes and are on medications that provide no benefit. Metformin,
sulfonylureas, and insulin cannot override the glucokinase set-point mechanism
and do not normalise glucose in confirmed GCK-MODY heterozygotes. Stopping
unnecessary medication removes side-effect risk, hypoglycaemia exposure, and
medication burden without any glycaemic cost.

Pregnancy is the exception. When a GCK-MODY carrier is pregnant, the key
variable is the fetal genotype. An unaffected fetus responds to maternal
hyperglycaemia with excess insulin, causing macrosomia. An affected fetus has
its own elevated set-point and grows normally. Fetal abdominal circumference on
ultrasound every two weeks from 26 weeks | Rudland VL. Diagnosis and management
of glucokinase monogenic diabetes in pregnancy: current perspectives. Diabetes
Metab Syndr Obes, 2019 is the
standard surrogate for fetal genotype: AC exceeding the 75th centile indicates
an unaffected fetus and warrants insulin therapy; AC at or below the 50th centile
suggests the fetus has inherited the variant and no treatment is needed.
Non-invasive fetal genotyping via cell-free fetal DNA is now available in
specialist centres and removes this ambiguity.

Interactions

Carriers of additional common type 2 diabetes risk alleles (such as rs5219 in
KCNJ11 or rs7903146 in TCF7L2) may have a modestly worse glycaemic trajectory
as these variants independently impair beta-cell function downstream of
glucokinase. Clinically, the GCK-MODY phenotype typically dominates, but
midlife weight gain or insulin resistance may compound the glucose elevation
beyond the expected stable range — patients with GCK-MODY whose glycaemia
worsens meaningfully after age 40 warrant reassessment.

Homozygous or compound heterozygous GCK mutations (two pathogenic alleles)
abolish glucokinase activity entirely, causing permanent neonatal diabetes
requiring insulin from birth — a qualitatively different, far more serious
condition than heterozygous MODY2. Parents who are both heterozygous GCK-MODY
carriers face a 25% probability per pregnancy of an affected homozygous infant,
and should discuss preconception genetic counselling.